Skip to content

Bare Platinum Coils Versus Second-generation Hydrocoils

Bare Platinum Coils Versus Second-generation Hydrocoils for the Endovascular Treatment of Ruptured Intracranial Aneurysms: a Randomized Controlled Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04988503
Enrollment
68
Registered
2021-08-03
Start date
2021-08-30
Completion date
2025-02-28
Last updated
2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysm, Ruptured, Intracranial Aneurysm

Keywords

aneurysms, embolization, rupture

Brief summary

Comparison of clinical and radiological outcomes between bare platinum coil group and second-generation hydrogel coils for treatment of ruptured intracranial aneurysms.

Detailed description

The investigators aimed to analyze whether the use of second-generation hydrogel coils for the treatment of ruptured intracranial aneurysms improves clinical and angiographic outcomes compared with the use of bare platinum coils.

Interventions

coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils

Sponsors

Pusan National University Yangsan Hospital
CollaboratorOTHER
Chungnam National University Sejong Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

bare platinum coils group versus second-generation hydrogel coil group

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 19 year old or older * untreated ruptured intracranial aneurysms with an anatomy such that endovascular treatment with either bare platinum or second-generation hydrogel coils was considered feasible. * person who agreed to study

Exclusion criteria

* contrast allgery (+) * combined other intracranial lesions (tumor, moyamoya disease, cerebral vascular diseases) * ineligible for coil embolization

Design outcomes

Primary

MeasureTime frameDescription
any recurrence rate after treatmentduring 12 months after coil embolizationany recurrence rate at 12 months after coil embolization

Secondary

MeasureTime frameDescription
packing density (%) after coil embolizationpacking density (%) after coil embolizationpacking density (%) after coil embolization
Procedural complicationduring coil embolizationProcedural complication
delayed cerebral ischemia during 12-month follow-up perioddelayed cerebral ischemia during 12-month follow-up perioddelayed cerebral ischemia during 12-month follow-up period
rate of retreatment during 12 months follow-up periodrate of retreatment during 12 months follow-up periodrate of retreatment during 12 months follow-up period
rate of ventriculoperitoneal shunt during 12-month follow-up periodrate of ventriculoperitoneal shunt during 12-month follow-up periodrate of ventriculoperitoneal shunt during 12-month follow-up period
coil's ease of manipulationduring coil embolizationcoil's ease of manipulation
good clinical outcome (mRS score ≤ 2) at 12-month follow-up periodgood clinical outcome (mRS score ≤ 2) at 12-month follow-up periodgood clinical outcome (mRS score ≤ 2) at 12-month follow-up period

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026